Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Thiomersal-free Hepatitis E Vaccine
NCT06564116Phase 4Completed
- Sponsor
- Xiamen Innovax Biotech Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of HEV 239 in hepatitis E (HEV) (2 arms), sponsored by Xiamen Innovax Biotech Co., Ltd. Primary endpoints: Seroconversion rate of anti-HEV IgG at Month 7, Anti-HEV IgG geometric mean concentration at Month 7 and 3 more. Started Mar 2023; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT06564116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564116.